tiprankstipranks
Advertisement

ACSG - ETF AI Analysis

Compare

Top Page

ACSG

American Century Small Cap Growth Insights ETF (ACSG)

Rating:64Neutral
Price Target:
ACSG, the American Century Small Cap Growth Insights ETF, earns a solid overall rating thanks to several strong small-cap growth holdings like Plexus and Argan, which show healthy revenue growth, solid backlogs, and positive earnings outlooks that support the fund’s quality. At the same time, weaker names such as Crinetics Pharmaceuticals and 10x Genomics, which face ongoing losses and profitability challenges, weigh on the rating. The main risk is that many top holdings trade at high valuations and some show mixed or bearish technical signals, which could make the fund more sensitive to market pullbacks.
Positive Factors
Strong Recent Performance
The ETF has delivered strong gains so far this year and over the past few months, showing solid recent momentum.
Top Holdings Showing Solid Growth
Many of the largest positions, including companies in health care and technology, have posted strong year-to-date gains that support the fund’s results.
Broad Sector Diversification
Holdings spread across many sectors, with meaningful weights in health care, technology, and industrials, help reduce the impact of weakness in any single industry.
Negative Factors
High U.S. Concentration
The fund is heavily focused on U.S. stocks, offering very limited exposure to other countries and less geographic diversification.
Moderately High Expense Ratio
The ETF’s expense ratio is on the higher side for a passive-style product, which can eat into long-term returns compared with lower-cost options.
Sector Tilt Toward Health Care and Technology
A large share of assets in health care and technology means the fund could be more sensitive to downturns or volatility in these growth-oriented sectors.

ACSG vs. SPDR S&P 500 ETF (SPY)

ACSG Summary

The American Century Small Cap Growth Insights ETF (ACSG) is an actively managed fund that focuses on smaller U.S. companies with the potential for fast growth, rather than tracking a set index. It invests across many areas of the economy, with a lot in health care and technology, and holds names like 10x Genomics and Qualys. Someone might consider ACSG to seek long-term growth and to diversify beyond large, well-known stocks. A key risk is that small-company shares can be more volatile, so the ETF’s value can rise and fall more sharply than the overall market.
How much will it cost me?The American Century Small Cap Growth Insights ETF (ACSG) has an expense ratio of 0.49%, meaning you’ll pay $4.90 per year for every $1,000 invested. This cost is higher than average because the fund is actively managed, which involves more research and decision-making compared to passively managed ETFs that track an index.
What would affect this ETF?The ACSG ETF, focused on U.S. small-cap growth companies, could benefit from innovation and expansion in sectors like technology and healthcare, which make up a significant portion of its holdings. However, it may face challenges during economic downturns, as small-cap stocks are often more volatile and sensitive to interest rate hikes or reduced consumer spending. Regulatory changes or sector-specific disruptions could also impact its performance negatively.

ACSG Top 10 Holdings

ACSG is leaning hard into U.S. small-cap growth, with a clear tilt toward health care and tech names that can really move the needle. Crinetics Pharmaceuticals and 10x Genomics have been rising sharply, acting as the fund’s main engines despite ongoing profitability questions. On the industrial side, Argan and Plexus are steady climbers, helping smooth out the ride. CECO Environmental, however, has been lagging lately, putting a small drag on results. Overall, performance is driven by a handful of nimble, high-growth U.S. specialists rather than broad market giants.
Name
Company Name
Weight %
Market Value
Market Cap
Yearly Gain
Overall Rating
Krystal Biotech0.96%$306.54K$9.66B141.09%
80
Outperform
Ceco Environmental0.89%$286.87K$4.14B58.44%
72
Outperform
10x Genomics0.89%$286.17K$6.61B375.79%
60
Neutral
Hexcel0.88%$280.81K$7.82B67.58%
73
Outperform
Plexus0.84%$269.54K$7.21B108.30%
75
Outperform
Argan0.81%$259.24K$8.37B154.85%
73
Outperform
Qualys0.79%$253.75K$6.35B45.28%
78
Outperform
Sensient Technologies0.79%$252.21K$5.53B11.52%
63
Neutral
Novanta0.77%$247.56K$6.29B44.83%
70
Neutral
Esco Technologies0.74%$238.77K$7.92B54.90%
70
Neutral

ACSG Technical Analysis

Technical Analysis Sentiment
Positive
Last Price
Price Trends
50DMA
48.47
Positive
100DMA
46.03
Positive
200DMA
43.76
Positive
Market Momentum
MACD
0.44
Negative
RSI
60.63
Neutral
STOCH
97.26
Negative
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For ACSG, the sentiment is Positive. The current price of undefined is equal to the 20-day moving average (MA) of 48.77, equal to the 50-day MA of 48.47, and equal to the 200-day MA of 43.76, indicating a bullish trend. The MACD of 0.44 indicates Negative momentum. The RSI at 60.63 is Neutral, neither overbought nor oversold. The STOCH value of 97.26 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ACSG.

ACSG Peer Comparison

Comparison Results
Name
Price
Price Target
AUM
Expense Ratio
Overall Rating
$31.99M0.49%
64
Neutral
$59.60M0.85%
66
Neutral
$52.45M0.95%
63
Neutral
$28.66M0.80%
60
Neutral
$8.12M0.55%
71
Outperform
$6.91M0.28%
61
Neutral
Performance Comparison
Ticker
Company Name
Price
Change
% Change
ACSG
American Century Small Cap Growth Insights ETF
50.27
10.22
25.52%
TMFS
Motley Fool Small-Cap Growth ETF
MMSC
First Trust Multi-Manager Small Cap Opportunities ETF
SGRW
Harbor Active Small Cap Growth ETF
SAWS
AAM Sawgrass US Small Cap Quality Growth ETF
FSEG
Fidelity Enhanced Small Cap Growth ETF
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
DisclaimerThis AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents
Advertisement